Maybe it happened to you this fall.
You finally had the conversation. You finally found a provider who listened. You walked out with a prescription for an estrogen patch, the thing so many of us were told for more than two decades was too dangerous to even discuss. And then the pharmacist looked at the screen, winced, and said the words: “We’re out. I don’t know when we’ll get more.”
After everything it took to get there. Out.
If that was you, here’s the first thing you need to hear: you are not the problem. You are the proof.
Key takeaways:
– The FDA initiated removal of boxed warnings on November 10, 2025, and approved changes for the first six products on February 12, 2026.
– The endometrial-cancer boxed warning on estrogen-alone systemic products was not removed.
– Hormone therapy use among US women 40+ fell from 4.4% (2007) to 1.7% (2023) (Mayo Clinic Proceedings).
– The FDA said estradiol patch supply nearly doubled in a year, yet demand still outpaced it.
– The FDA advises asking your pharmacist about other approved patches, talking to your provider, and not stopping treatment on your own.
What changed on November 10
One year ago, on November 10, 2025, the FDA formally requested labeling changes to menopausal hormone therapy products, starting the removal of the boxed “black box” warnings about cardiovascular disease, breast cancer, and probable dementia. On February 12, 2026, the FDA approved those labeling changes for the first six products. Twenty-nine manufacturers had filed.
One warning stayed, and it matters: the boxed warning for endometrial cancer on systemic estrogen-alone products was not removed. The label also still recommends starting within 10 years of menopause onset or before age 60.
That’s the regulatory action, stated plainly, because it’s a fact. What it means for your body is a conversation with your provider. Early research is still being weighed, and clinicians are re-examining how they counsel patients. We’ll keep those two things separate every time we write about this, because blurring them is how women got misled in the first place.
The number from right before the change
To understand why a shortage happened, look at where things stood just before the labels changed.
A large Mayo Clinic analysis published in June 2026 in Mayo Clinic Proceedings tracked hormone therapy use among American women 40 and older. In 2007, 4.4% were using it. By 2023, it had fallen to 1.7%. Among women aged 50 to 59, the group most likely to benefit, only 3.5% were using it in 2023.
Read that again. More podcasts, more books, more Instagram accounts, more menopause talk than ever before. And treatment at its lowest point in about two decades.
The FDA put the scale of it plainly when it approved the label changes: in 2020 about 41 million US women were aged 45 to 64, while only about 2 million women aged 46 to 65 received a hormone therapy prescription.
That’s not a lack of need. That’s a lack of permission.
The treatment gap was always this wide
The shortage didn’t create a gap. It exposed one that was already there.
About 80% of women get hot flashes. Only 20 to 30% are ever treated. That gap isn’t made of medicine. It’s made of silence.
And those hot flashes aren’t a quick phase you can wait out over a long weekend. In the long-running SWAN study, frequent hot flashes lasted a median of about 7.4 years, and longer for women whose symptoms started early. Black women’s lasted longest, around a decade.
Seven years of interrupted sleep. Seven years of sweating through meetings. Seven years of being told to layer your clothes and carry a fan.
So when the label changed, and women finally felt permitted to ask, they weren’t asking for something new. They were asking for relief they’d needed for years, some of them for most of a decade.
Then came September
On September 3, 2026, the FDA posted an update acknowledging “reports of patients having difficulty readily accessing their usual estradiol transdermal patches due to increased demand.” The agency tied that demand directly to the November 2025 labeling change.
And here’s the line that deserves a spotlight: over the last year, the FDA said, the supply of FDA-approved estradiol patches “has nearly doubled.”
Nearly doubled. And it’s still not enough.
Think about what that means. The manufacturers weren’t asleep. Production roughly doubled in a year, and women still couldn’t reliably fill their prescriptions. The demand wasn’t a trickle that grew. It was a flood that had been held behind a wall of fear, dismissal, and outdated warnings for a very long time.
The shortage is the receipt. It’s the clearest evidence we’ve ever had of how many women were suffering quietly, told they were fine, when they simply weren’t being treated.
“But they said it was a fad”
You’ll hear the eye-roll version of this story. Menopause is trendy. Everybody’s suddenly on hormones. It’s hype.
Let’s be real about who’s telling that story and why. When men’s prescriptions spike after a new approval, nobody calls it a fad. It’s called unmet need. It’s called a market. It’s called progress.
When women’s prescriptions rise after generations of being told to grit their teeth, suddenly it’s a trend.
That’s not skepticism. That’s the same old dismissal in a new outfit.
The women filling these prescriptions aren’t chasing a fad. They’re the ones who spent years hearing “it’s just stress,” who sat through more appointments than anyone should need, who were told their anxiety or their stress was the whole story. Many of them are finally getting a real conversation with a provider for the first time. That’s not hype. That’s catch-up.
What to do if your pharmacy is out
Here’s where we get practical, because being right doesn’t fill a prescription.
The FDA’s own advice for patients who can’t get their usual patch comes down to three things:
1. Ask the pharmacist about other FDA-approved estradiol patches. Different manufacturers make patches with the same active ingredient. Availability varies by brand and by location, so ask what they can get and whether another pharmacy nearby has stock. Don’t swap anything without your prescriber’s okay; just ask the question.
2. Talk to your provider about alternatives. Estrogen comes in more than one form, and there are non-hormonal options too. Two non-hormonal prescription drugs are FDA-approved for moderate-to-severe hot flashes: Veozah (fezolinetant, approved May 2023) and Lynkuet (elinzanetant, approved October 24, 2025). Both carry liver-related monitoring requirements, so they’re a real conversation, not an automatic swap. And for the roughly 9% of women with a genuine contraindication to hormone therapy, these options matter even more.
3. Don’t just stop. The FDA is explicit: don’t discontinue your medication without talking to your healthcare provider. If you’re running low, call before you run out, not after.
A script you can use, word for word: “My pharmacy can’t fill my estradiol patch. Can we plan a backup, whether that’s another brand, another form, or another option, so I’m not left without treatment?”
That’s not being difficult. That’s being prepared.
What a year actually changed
Here’s the honest scorecard, one year in.
What changed: the label. The conversation. The permission. Millions of women who were told “no” now hear “let’s talk about it.” Demand surged so fast that nearly doubling production couldn’t keep up.
What didn’t change: the training gap. Only 6.8% of graduating residents felt adequately prepared to manage menopause. There are about 1,300 certified menopause practitioners for roughly 6,000 women reaching menopause every day. The label changed overnight. The workforce did not.
What’s still true: hormone therapy remains the most effective treatment for hot flashes, and it isn’t right for everyone. Nobody should be pressured onto it, and nobody should be pressured off it. The decision belongs to you and a provider who takes you seriously.
The point: the barrier moved. The bottleneck didn’t.
One year later, the woman at the counter
Let’s go back to the pharmacy counter.
A year ago, many of the women standing in that line wouldn’t have been there at all. They’d have been at home, fanning themselves, lying awake at 3 a.m., apologizing for their moods, sure it was their fault. Now they’re in line, with a prescription, asking for help.
The shortage is frustrating. It’s also a picture of millions of women who stopped waiting to be believed.
You were never overreacting. There were just more of us than anyone bothered to count.
— Delaney
-
Demand surged after the FDA began removing boxed warnings on menopausal hormone therapy in November 2025. On September 3, 2026, the FDA acknowledged patients were struggling to get estradiol patches “due to increased demand,” even though supply had “nearly doubled” in a year.
-
On September 3, 2026, the FDA acknowledged that patients were having difficulty accessing their usual estradiol patches due to increased demand, though it said patches
-
The FDA initiated removal of the boxed warnings on cardiovascular disease, breast cancer and probable dementia on November 10, 2025, and approved the first six products’ label changes on February 12, 2026. The endometrial-cancer boxed warning on estrogen-alone systemic products remains.
-
A Mayo Clinic Proceedings analysis found that use among US women 40+ fell from 4.4% in 2007 to 1.7% in 2023; among women 50 to 59, it was 3.5%.
-
Ask your pharmacist about other FDA-approved estradiol patches, talk to your provider about alternatives, and don’t stop treatment without your provider’s guidance.
-
Yes. Veozah (fezolinetant, 2023) and Lynkuet (elinzanetant, 2025) are FDA-approved non-hormonal options. Both require liver-related monitoring; discuss them with your provider.
-
Not automatically. The label recommends starting within 10 years of menopause or before 60, and about 9% of women have a genuine contraindication. It’s an individual decision with your provider.
The FDA story, the funding story, and the full science of what’s happening in your body, all in one place: You’re Not Crazy... You’re Menopausal: Science, Strategies, and Swearing Through the Hormonal Apocalypse at notcrazymovement.com/book. Heading into an appointment? Get the free 7-Day Symptom Tracker + Doctor Visit Guide at notcrazymovement.com.
Medical note: This article is educational and is not medical advice. Hormone therapy and non-hormonal medications each carry benefits and risks that differ by person and by form. Talk to your healthcare provider before starting, stopping, or changing any treatment.
Sources & References
1. U.S. Food and Drug Administration. FDA Update on Estradiol Transdermal Patch Availability. September 3, 2026. fda.gov
2. U.S. Food and Drug Administration. FDA Approves Labeling Changes for Menopausal Hormone Therapy Products. Press announcement, February 12, 2026. fda.gov
3. U.S. Food and Drug Administration. Drug Safety Communication on menopausal hormone therapy labeling, November 10, 2025.
4. Mayo Clinic. “Hormone therapy use for menopause declines despite proven benefits, study finds.” June 1, 2026, reporting “United States Menopausal Hormone Therapy Usage Trends,” Mayo Clinic Proceedings. EurekAlert
5. U.S. Food and Drug Administration. Approval of Veozah (fezolinetant), May 2023; approval of Lynkuet (elinzanetant), October 24, 2025.
6. Avis NE, et al. Duration of menopausal vasomotor symptoms over the menopause transition (SWAN). JAMA Internal Medicine, 2015.
7. Allen JT, et al. Menopause education in US obstetrics and gynecology residency programs. Menopause, 2023; The Menopause Society, resident preparedness survey and certified practitioner count.
